Genmab — Juni 2017
-
Fra Myeloma Crowd: Populær og detaljeret omtale af Celgene/Heidelbergs bispecifikke BCMA/cd3-studier i MM, som starter til næste år. https://www.myelomacrowd.org/full-show-new-bi-specific-antibody-hitting-two-targets-in-myeloma-dirk-hose-md-and-anja-seckinger-md-university-of-heidelberg/
-
Rookie-spørgsmål her til Genmab-chatten: Ejer Janssen rettighederne til samtlige fremtidige anvendelser af Darzalex eller er det kun MM?
-
Ja,
Janssen ejer Darzalex i alle indikationer -
Tak. Ved du om Genmab får 20% af alle indtægter så snart det samlede salg når over 3 mia. USD (hvis jeg husker rigtigt) eller er det 3 mia. for hver af de enkelte indikationer?
-
EHA is happening now, started
yesterday https://www.ehaweb.org/congress-and-events/22nd-congress/program-by-day-2/ -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind